scholarly journals Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance

2012 ◽  
Vol 93 (3) ◽  
pp. 252-259 ◽  
Author(s):  
D Gonzalez de Castro ◽  
P A Clarke ◽  
B Al-Lazikani ◽  
P Workman
Keyword(s):  
Drug Resistance ◽  
Molecular Diagnostics ◽  
Predictive Biomarkers ◽  
Personalized Cancer Medicine ◽  
Cancer Medicine ◽  
Personalized Cancer

scholarly journals Personalized Cancer Medicine in the Media: Sensationalism or Realistic Reporting?

2021 ◽  
Vol 11 (8) ◽  
pp. 741
Author(s):  
Katherine Hicks-Courant ◽  
Jenny Shen ◽  
Angela Stroupe ◽  
Angel Cronin ◽  
Elizabeth F. Bair ◽  
...  
Keyword(s):  
Personalized Medicine ◽  
Media Coverage ◽  
Disease Risk ◽  
Federal Drug Administration ◽  
Personalized Cancer Medicine ◽  
The Media ◽  
Cancer Medicine ◽  
Media Reports ◽  
Personalized Cancer ◽  
Standard Tests

Background: Given that media coverage can shape healthcare expectations, it is essential that we understand how the media frames “personalized medicine” (PM) in oncology, and whether information about unproven technologies is widely disseminated. Methods: We conducted a content analysis of 396 news reports related to cancer and PM published between 1 January 1998 and 31 December 2011. Two coders independently coded all the reports using a pre-defined framework. Determination of coverage of “standard” and “non-standard” therapies and tests was made by comparing the media print/broadcast date to the date of Federal Drug Administration approval or incorporation into clinical guidelines. Results: Although the term “personalized medicine” appeared in all reports, it was clearly defined only 27% of the time. Stories more frequently reported PM benefits than challenges (96% vs. 48%, p < 0.001). Commonly reported benefits included improved treatment (89%), prediction of side effects (30%), disease risk prediction (33%), and lower cost (19%). Commonly reported challenges included high cost (28%), potential for discrimination (29%), and concerns over privacy and regulation (21%). Coverage of inherited DNA testing was more common than coverage of tumor testing (79% vs. 25%, p < 0.001). Media reports of standard tests and treatments were common; however, 8% included information about non-standard technologies, such as experimental medications and gene therapy. Conclusion: Confusion about personalized cancer medicine may be exacerbated by media reports that fail to clearly define the term. While most media stories reported on standard tests and treatments, an emphasis on the benefits of PM may lead to unrealistic expectations for cancer genomic care.

scholarly journals Personalized cancer medicine and the future of pathology

2011 ◽  
Vol 460 (1) ◽  
pp. 3-8 ◽  
Author(s):  
H. Moch ◽  
P. R. Blank ◽  
M. Dietel ◽  
G. Elmberger ◽  
K. M. Kerr ◽  
...  
Keyword(s):  
Personalized Cancer Medicine ◽  
The Future ◽  
Cancer Medicine ◽  
Personalized Cancer

scholarly journals Getting to personalized cancer medicine

Cancer ◽  
2007 ◽  
Vol 110 (8) ◽  
pp. 1641-1643 ◽  
Author(s):  
Carolyn Compton
Keyword(s):  
Personalized Cancer Medicine ◽  
Cancer Medicine ◽  
Personalized Cancer
Sign in / Sign up

Export Citation Format

Share Document